Investigational MS TreatmentTrial (NAPSA)—Researchers have begun enrolling patients into a global study looking at the use of an investigational drug, laquinimod—administered once daily in pill form. “One of the biggest inconveniences is the way that I have to take the injections,” said Ann, an MS patient. “When I heard there was going to be a possibility of an oral product, I was ecstatic.” About The Study Called “Allegro” (assessment of oral laquinimodin preventing progression of multiple sclerosis), the study will compare the effectiveness, safety, and tolerability (side effects) of laquinimod with that of a sugar pill, or placebo, in the treatment of RRMS (relapsingremitting MS). The researchers plan to enroll approximately 1,000 patients in the study, following the patients for two years. It is encouraging to know that researchers are pursuing oral therapy options for MS. It is encouraging to know that researchers are pursuing oral therapy options for MS. Trial participants will receive the study drug and related physician visits at no charge. To Enroll If you or a loved one is between the ages of 18 and 55 years, has been diagnosed with MS, and is interested in becoming a trial participant for the Allegro study, ask your doctor if it is right for you. For more information, visit www.TevaClinicalTrials.com or call (866) 550-0614. —eee ee eee eee ee ee ee ee ee ee ee ee Qe cc ess cs ss sssses Note to Editors:Allegro is a pivotal Phase III study sponsored by Teva Pharmaceutical Industries Ltd.
